Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2224-2229

  Boehme, Michael ^a   Kaehne, Fenja ^a   Kuehne, Anna ^a   Bernhardt, Wanja ^a   Schröder, Matthias ^b   Pommer, Wolfgang ^b   Fischer, Christoph ^b   Becker, Helmut ^b   Müller, Christian ^a   Schindler, Ralf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KfH Dialysis Clinics Nordgraben/Bismarckstr   (Germany)

Author keywords

C reactive protein; Cardiovascular disease; Chronic renal failure; Haemodialysis; Pentraxin

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; PENTRAXIN 3;

ADULT; ARTERY DISEASE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MORBIDITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; TIME;

ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INTERLEUKIN-6; MODELS, STATISTICAL; PERITONEAL DIALYSIS; RENAL DIALYSIS; SERUM AMYLOID P-COMPONENT;

EID: 34547830311     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl747     Document Type: Article

References (23)

1. Peng N, Liu JT, Gao DF, Lin R, Li R. Angiotensin II-induced C-reactive protein generation: Inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 2006; in press
2. Krupinski J, Turu MM, Martinez-Gonzalez J et al. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 2006; 37: 1200-1204
3. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Ann Rev Immunol 2005; 23: 337-366
4. Bottazzi B, Garlanda C, Salvatori G et al. Pentraxins as a key component of innate immunity. Curr Opin Immunol 2006; 18: 10-15
5. Latini R, Maggioni AP, Peri G et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354
6. Hampel DJ, Pratschke J, May G, Reinke P, Schindler R. Living kidney donation: Anemia and inflammation in the early post-operative period. Transplant Proc 2006; 38: 661-663
7. Bottazzi B, Vouret Craviari V, Bastone A et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272: 32817-32823
8. Garlanda C, Hirsch E, Bozza S et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420: 182-186
9. Souza DG, Soares AC, Pinho V et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002; 160: 1755-1765
10. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-2485
11. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
12. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments]. Lancet 1997; 349: 462-466
13. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126
15. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152
16. Docci D, Bilancioni R, Buscaroli A et al. Elevated serum levels of C-reactive protein in hemodialysis patients. Nephron 1990; 56: 364-367
17. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-960
18. Zimmermann J, Herrllinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
19. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105
20. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21: 1915-1920
21. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
22. Peri G, Introna M, Corradi D et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-641
23. Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221